Microfluidic Organoid Insert for High-Throughput Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods face challenges in predicting individual patient responses due to the limitations of two-dimensional cell cultures and animal-based models, which fail to accurately mimic the complex tumor microenvironment, leading to ineffective treatments and high costs.
Innovation Solution
A multifunctional microfluidic device for culturing cell spheroids or organoids that allows for simultaneous loading of culture medium, cells, and extra-cellular matrix components into multiple microwells, enabling controlled delivery of therapeutics and sequential or combinatorial drug treatments, while replicating the tumor microenvironment for high-throughput drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If two-dimensional monolayer culture methods are used, then simplicity and ease of operation are maintained, but the ability to replicate complex tumor microenvironment interactions and tissue-specific architecture is lost
Solution Approach 1:
The patent transitions from two-dimensional monolayer culture to three-dimensional organoid culture within microwells. This dimensional change enables cells to self-organize into spheroidal structures that better mimic in vivo tissue architecture, cell-cell interactions, and tumor microenvironment complexity while maintaining the simplicity of well plate-based culture systems.
Solution Approach 2:
The invention embeds multiple functional components within a hierarchical structure: organoids are cultured within individual microwells, which are arranged in multi-well plates. The microwell insert structure nests delivery channels, reservoirs, and microwells in a compact integrated device that fits within standard plate formats, enabling complex 3D modeling without sacrificing operational simplicity.
2Reliability
If patient-derived organoids are used for personalized medicine, then predictive accuracy for treatment response is improved, but the complexity of establishing and maintaining these models increases
Solution Approach 1:
The microfluidic device is designed as a universal platform that can accommodate multiple organoid cultures simultaneously in a single device. The modular microwell array allows parallel processing of multiple patient samples, and the integrated delivery system can administer various therapeutics through common access points, reducing per-sample complexity while maintaining high predictive accuracy.
Solution Approach 2:
The device segments the culture system into independent microwells, each containing individual organoids that can be treated and analyzed separately. This segmentation allows for high-throughput screening of multiple therapeutic agents across multiple patient-derived organoids simultaneously, distributing the complexity across parallel simple units rather than requiring a single complex system.
3Reliability
If conventional organoid culture methods are used, then tissue microenvironment complexity is achieved, but high-throughput drug screening capability is lost
Solution Approach 1:
The invention merges the advantages of 3D organoid culture with high-throughput screening capabilities by integrating multiple microwells containing complex tumor microenvironments into a single microfluidic device. The unified delivery system combines multiple therapeutic access points and enables simultaneous administration of various agents across numerous organoids, achieving both biological fidelity and screening productivity.
Solution Approach 2:
The device employs microfluidic hydraulic systems with integrated pumps and delivery channels to automatically transport therapeutics through the device architecture. This automated fluid delivery system enables high-throughput drug screening by systematically distributing multiple compounds to multiple organoids without manual intervention, while maintaining the complex 3D tissue structures within each microwell.
4Measurement precision
If multiple therapeutics are delivered to individual microwells under temporal control, then precision in evaluating treatment responses is improved, but the complexity of the delivery system increases
Solution Approach 1:
The device incorporates pre-programmed temporal delivery schedules for multiple therapeutics through its microfluidic control system. Therapeutic agents are pre-loaded into reservoirs with scheduled release timing, enabling precise evaluation of sequential and combinatorial treatment protocols without requiring complex real-time control operations during the experiment.
Solution Approach 2:
The microfluidic delivery channels act as intermediaries between the therapeutic reservoirs and the organoids in micrawells. This intermediary system automates the precise temporal and spatial delivery of multiple therapeutics, reducing the operational complexity for the user while maintaining high measurement precision for treatment response evaluation.
Data Source
AI summary
A microfluidic device is provided for culturing cell spheroids or organoids and therapeutics screening, the microfluidic device comprising a shell and an at least one sector, the shell comprising a multiplicity of segments, each segment defined by a center point, an outer wall, and radially extending walls that radiate from the center point to the outer wall, the sector retained in the segment and comprising a plurality of microwells, a loading well which is in elevated relationship with the plurality of microwells, a plurality of micro-troughs which extend between the loading well and the plurality of microwells, such that each microwell is in fluid communication with the loading well via a micro-trough, a delivery port, and a plurality of delivery troughs which extend between the delivery port and the plurality of microwells such that each microwell is in fluid communication with the delivery port via a delivery trough.